middle.news
How Dimerix’s $55M Licensing Boost is Narrowing Losses and Advancing Phase 3 Trial
2:14am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Dimerix’s $55M Licensing Boost is Narrowing Losses and Advancing Phase 3 Trial
2:14am on Saturday 30th of August, 2025 AEST
Key Points
22% reduction in net loss to $13.25 million for FY2025
Received over AU$55 million in upfront and milestone licensing payments
Expanded global licensing agreements with Amicus Therapeutics and FUSO Pharmaceutical Industries
Progressed Phase 3 ACTION3 clinical trial across 22 countries with pediatric sites activated
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE